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Background: The 5-year survival of patients receiving standard-of-care chemotherapy for metastatic
gastric cancer (MGC) to the liver is <2%. This review examines the published data on liver resections for
MGC and analyses the rationale for potentially aggressive surgical management.
Methods: A search of the PubMed and Scopus databases was used to identify studies published in
English from 1990 to 2009 that reported on 10 or more patients who underwent liver resections for MGC.
All available clinicopathologic data were analysed. In particular, we examined longterm survival and the
characteristics of individuals surviving for >5 years.
Results: Nineteen studies reported on 436 patients. Median 5-year survival was 26.5% (range: 0–60%).
Overall, 13.4% (48/358) of patients were alive at 5 years and studies with extended follow-up reported
that 4.0% (7/174) of patients survived for >10 years. Overall in-hospital mortality was 3.5% (12/340
patients); however, the median mortality rate across the studies was 0%. No prognostic factor was found
to be consistently statistically significant across these small studies.
Conclusions: Despite the limitations of any analysis of retrospective data for highly selected groups of
patients, it would appear that liver resections combined with systemic therapy for MGC can result in
prolonged survival.
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Introduction
Gastric cancer is the fourth most common cancer worldwide and
has an incidence of 989 598 and an annual mortality close to
738 069.1 In the USA, the incidence of gastric cancer has steadily
declined in recent years and it now represents the 14th most
common cancer, and accounts for 1.5% of all new diagnoses and
5.2% of all cancer deaths.2,3 Approximately 21 130 people will
develop gastric cancer in the USA this year and an estimated
10 620 individuals will die from the disease.2,3
At the time of diagnosis, 35% of patients present with evidence
of distant metastases and 4–14% have metastatic disease to the
liver.4–6 In patients who undergo gastric resection with curative
intent, hepatic recurrences are common. A study from the Memo-
rial Sloan-Kettering Cancer Center (MSKCC) described patterns
of recurrence in completely resected gastric adenocarcinomas
in a large series of patients (n = 1172) and found liver-specific
recurrence rates of 37%.7
There are no adequate large prospective studies detailing
the natural history of metastatic gastric carcinoma and longterm
survival. However, two small randomized trials compared best
supportive care vs. combination chemotherapy and found that no
patients treated with supportive care lived for >1 year.8–11 Survival
data for patients with metastatic gastric cancer (MGC) to the liver
only are also limited. In a study analysing 643 patients enrolled in
five separate chemotherapy trials by the Japanese Clinical Oncol-
ogy Group (JCOG), 5-year survival for patients with metastases
confined to the liver and treated with systemic therapy alone
was 1.7%.12 Palliative chemotherapy using various regimens has
been widely used as the treatment of choice, but only modest
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improvements in overall survival have been observed, with
median survival increasing from approximately 3 months to 7–15
months. Longterm survival is rarely reported.8–13
Liver resection is now a routine procedure at specialty centres
around the world. Improvements in the understanding of
anatomy, physiology, perioperative care and surgical technique
have reduced operative mortality in most tertiary referral cancer
centres to <2%.14 For hepatic colorectal metastases, retrospective
studies involving thousands of patients show that surgical resec-
tion can yield 5-year survival rates of 35–61%.15 Similar results
have been observed following resections of hepatic metastases
from primary neuroendocrine tumours.16 Thus, surgical manage-
ment of metastatic disease is now considered the standard of care
for these two malignancies.
Identifying the patients who are most likely to benefit from
surgery is critical to improving treatment options for patients with
MGC. Therefore, the aim of this review was to examine the current
evidence for longterm survival following hepatic resections for
metastatic gastric adenocarcinomas and to determine factors that
may be used in a prospective fashion to identify the patients who
are most likely to benefit from operative management.
Materials and methods
A comprehensive PubMed and Scopus database search was per-
formed to identify all studies published in English from 1990 to
2009 reporting on liver resections for MGC. A total of 26 studies
were identified, from which studies reporting on <10 patients and
studies lacking longterm outcome or survival data were excluded,
leaving 21 studies for analysis (Fig. 1).17–37 Data from Miyazaki
et al.33 and Sakamoto et al.24 were not used in calculating the total
number of patients or survival statistics because more recent
follow-up data on the same patient populations were reported by
Ambiru et al.29 and Koga et al.,22 respectively.
Data were collected and evaluated on the size of the series,
the year and country of publication, patient and primary
tumour characteristics, whether hepatic surgeries were completed
in synchronous (together with gastrectomy) or metachronous
(after gastrectomy) fashion, the type of operative intervention
(wedge resections, anatomic segmentectomies or hepatectomies),
and operative morbidity and mortality. Longterm outcome
evaluations included 1-, 3- and 5-year actuarial survival based on
Kaplan–Meier curves, along with the number of patients alive for
5 years at the time of reporting, excluding duplicated data (Fig. 1).
Detailed profiles of individuals surviving for >5 years were analy-
sed and used to generate potential selection criteria for patients
who might benefit from liver resection in MGC.
Results
Patients
Between 1990 and 2008, 436 patients at multiple institutions
in seven countries were reported in 21 studies to have under-
gone liver resection for metastatic gastric adenocarcinoma
(Table 1).17–37 These included 279 patients (64%) from Japan,
114 patients (26%) from Europe, 33 patients (8%) from South
Korea, and only 10 patients (2%) from the USA. Patient gender
was defined for 375 patients, including 284 males (76%) and 91
females (24%). The median age of patients by series ranged from
55 years to 67 years.
Studies excluded (n = 2)
Excluded in favour of  newer reports by the
same group on previously reported
patients24,33  
Studies included in the analysis
(n =19)
Studies with usable information, 
by outcome
(n =19)
All studies were found to be
appropriate: > 10 patients, inclusion
of longterm survival data
Potentially appropriate studies on
liver resections for metastatic
gastric cancer (n = 19)




reporting on liver resections for
metastatic gastric cancer (n = 26) Studies excluded (n = 5)
Excluded for reporting < 10 patients
or no survival data 
Figure 1 Flow chart showing details of the PubMed article selection process
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Development of hepatic metastases from
gastric cancer
Rates of synchronous and metachronous disease varied depending
on the particular definitions applied by each study. Commonly,
synchronous disease was defined as metastases found either at the
time of primary tumour diagnosis or within 1–6 months of the
primary gastric resection. Data on the occurrence of hepatic gastric
cancer metastases were reported in 16 studies.17–23,25–31,34,35 Overall,
58% (197/342) of patients had synchronous metastatic disease;
proportions of patients with synchronous metastatic disease in
individual studies lay in the range of 42–100% (Table 2).
The median time to first diagnosis of metachronous disease
(median disease-free interval [DFI]) to the liver was 12.5 months
(range: 10.1–21 months).18,19,22,23,26–28,31,34,35
Clinicopathologic features of the primary gastric
adenocarcinoma
Clinicopathologic features of the primary gastric cancer are
summarized in Table 2.
Clinicopathologic features of hepatic metastases
from gastric cancer
Clinicopathologic features of the hepatic metastases are shown in
Table 3.
Adjuvant therapy
Nine studies19,21,22,26,27,29,32,34,35 reported on adjuvant therapy
specifically to treat hepatic disease. Overall, 48% (119/248) of
patients received some form of liver-specific adjuvant systemic
Table 1 Longterm survival of patients after resection of hepatic metastases from gastric adenocarcinomas
Authors Country Year Patients,
n




Median Mean 1-year 3-year 5-year
Morise et al.17 Japan 2008 18 13 – 56 27 27 3a 0
Thelen et al.18 Germany 2008 24 – – 53 22 15 2 1
Cheon et al.19 S. Korea 2008 22 17 – 77 30 23 3 1
Ueda et al.b20 Japan 2008 15 – – 80 60 60 3 0
Sakamoto et al.21 Japan 2007 37 31 – – – 11 2 0
Koga et al.22 Japan 2007 42 34 – 76 48 42 8 2
Adam et al.36 France 2006 64 15 – – – 27 – –
Hirai et al.37 Japan 2006 14 – – – – 42 – 0
Roh et al.23 S. Korea 2005 11 19 – 73 38 38 1 0
Shirabe et al.25 Japan 2003 36 – – 64 26 26 4 0
Okano et al.26 Japan 2002 19 21 – 77 34 34 3 0
Saiura et al.27 Japan 2002 10 25 27 50 30 20 2 3
Zacherl et al.28 Austria 2002 15 9 16 36 29 – 0 1
Ambiru et al.29 Japan 2001 40 12 – – – 18 6 0
Imamura et al.30 Japan 2001 17 – – 47 22 0 0 0
Fujii et al.31 Japan 2001 10 16 – 60 20 10 1 1
Elias et al.32 France 1998 11 – – 90 35 – 4 –
Ochiai et al.34 Japan 1994 21 – – – – – 4 –
Bines et al.35 USA 1993 10 – – 45 30 2 3
Total – 436 – – – – – 48 (13.4%) 12 (3.5%)
aAlive at 4 years at time of follow-up
bThree patients received microwave ablation therapy
Table 2 Clinicopathologic features of primary gastric adenocarcinomas
Depth Lymph node Lymphatic invasion Venous invasion Differentiation Synchronous
17–19,21–23,26–31 8,17–19,21–23,26–31,34 17–19,21–23,25–31 17–19,21–23,25–31 17–19,21–23,26–31,35 16–31,33,34
T1–T2 N0–N1 No No Poor–moderate No
56% (114/202) 48% (80/166) 32% (31/97) 37% (43/115) 83% (86/104) 42% (145/342)
T3–T4 N2–N3 Yes Yes Well Yes
44% (88/202) 52% (86/166) 68% (66/97) 63% (72/115) 15% (16/104) 58% (197/342)
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chemotherapy, 15% (37/248) of patients received hepatic arterial
infusion (HAI), and 1% (2/248) of patients underwent concurrent
intraoperative radiation. Four studies19,21,27,35 reported on the
specific agents used, which included 5-flourouracil (5-FU),21,27,29,35
cisplatin,19,21 anthracylin,19 aclarubicin29 and mitomycin C9
through HAI.
Patterns of recurrence
Nine studies reported on disease recurrence.18,19,21–23,25,26,29,31
Detailed site-specific recurrence data were not available in most
reports. However, high rates of recurrent disease at any site were
uniformly described in all studies (64–91%). Overall, the recur-
rence rate at any site was 76% (183/241 patients) and the hepatic-
specific recurrence rate was 56% (136/241 patients). Data on
whether recurrences were localized to the resection site were not
specified.
Morbidity and mortality after liver resection
Mortality rates were reported in 16 studies (Table 1).17–23,25–31,35,37
Nine studies (207 patients) had no deaths in their
series.17,20,21,23,25,26,29,30,37 The median mortality rate across the
studies was 0% (range: 0–30%). Analysis of all patients indicated
that overall in-hospital mortality was 3.5% (12/340 patients) and
30-day mortality was 0.9% (3/340 patients). Minimal data regard-
ing the morbidity of these operations were provided. Thelen
et al.18 reported that four of 24 patients developed postoperative
complications consisting of liver insufficiency (one patient),
pneumonia (one patient) and pleural effusion (two patients).
Zacherl et al.28 reported on seven of 15 patients who developed
postoperative complications. Only four of these patients were cat-
egorized as demonstrating major complications, but no further
details were available. Two of these patients were re-operated for
multiple complications such as bleeding, anastomotic failure, pan-
creatitis and peritonitis. Excluding three patients who were
counted as in-hospital mortalities, Bines et al.35 reported three of
10 patients who developed complications (pulmonary embolus,
pleural effusion with arrhythmia, wound infection) after hospital
discharge.
Survival rates
Actuarial 1-, 3- and/or 5-year survival rates were reported in 18
studies (Table 1).17–23,25–32,35–37 Longterm 5-year survival was
reported in 16 studies.17–23,25–27,29–31,35–37 Eleven studies reported
5-year survival rates of 20%17,19,20,22,23,25–27,35–37 and three studies
reported 5-year survival rates of 10–19%.21,29,31 If data from all
the studies are combined, the median 1-, 3- and 5-year survival
rates are 62.0%, 30.0% and 26.5%, respectively. Seventeen
studies17–22,25–32,34,35 provided information about the number of
patients still alive 5 years after surgical resection of metastatic liver
disease. Although follow-up was not complete, 13.4% (48/358) of
patients were still alive 5 years after surgery. Seven studies reported
a median survival of >15 months.19,21–23,26,27,31 The median survival
across the studies was 17 months.
Detailed analyses of data for a total of 29 patients who survived
for >5 years were reported by eight studies.20,22,23,25,27,31,34,35 Interest-
ingly, 17 of the 29 patients had synchronous lesions, which sug-
gests that longterm survival may be attainable despite advanced
disease presentation in highly selected individuals. Of the 29 long-
term survivors, 26 had a single lesion resected and only three
patients had multiple metastatic nodules removed. No strong pat-
terns were observed regarding patient sex, tumour differentiation
status, lymph node status or type of surgery performed. Seven of
the 29 patients survived for 10 years. All patients who survived
for 10 years had only one lesion removed and four of six presented
with a well-differentiated histological grade and four of five
patients had a T1–T2 primary lesion. Surprisingly, six of the seven
10-year survivors initially presented with synchronous disease.
Two patients underwent wedge resections, two had formal lobec-
tomies, one had a segmentectomy and for one patient the specific
liver resection was not clearly documented.
Prognostic factors
Ten studies17,18,21,22,25,26,28,29,31,34 evaluated various prognostic factors
for patients undergoing liver resections for gastric adenocarcino-
mas. The categories analysed were demographics (age, gender),
primary tumour characteristics (size, location, depth of invasion,
tumour grade, lymphatic invasion, venous invasion, presence
of tumour lymphocytes, fibrous pseudocapsule, lymph node
involvement), characteristics of liver metastases (size, number,
distribution, timing of resection, type of resection, resection
margin, DFI), preoperative carcinoembryonic antigen (CEA)
level, and use of liver-specific adjuvant therapies.
Univariate analysis showed a positive resection margin to be a
significant predictor of poor outcome in two studies (P = 0.005,
Table 3 Clinicopathologic features of hepatic metastases
Lesions, n Distribution Surgical procedure
Wedge Segment Lobe
17–19,21–23,26–31 17–19,21–23,26–31 17–19,21–23,25,26,28–31,34,35 17–19,21–23,25,26,28–31,34,35 17–19,21–23,25,26,28–31,34,35
1 Unilobar 50% (119/240) 31% (76/240) 19% (45/240)
61% (162/265) 77% (172/222)
>1 Bilobar
39% (103/265) 23% (50/222)
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P = 0.024).18,29 Primary tumour characteristics such as increased
depth of invasion (T-stage) were significant in three studies
(P = 0.02, P = 0.06, hazard ratio 5.60 [1.42–22.15])17,22,34 and a
higher degree of lymphatic invasion (P = 0.002, P = 0.0001)17,25
and venous invasion (P = 0.02, P = 0.0069)21,25 were significant
in two. A moderate or poorly differentiated primary tumour
histologic grade (P = 0.015)26 also predicted worse outcome in
one study. By contrast, the presence of lymphocytic aggregation
(P = 0.026)31 and a fibrous pseudocapsule (P = 0.02)26 on primary
tumours predicted improved outcome in single reports.
Characteristics of gastric liver metastases that predicted worse
outcomes in at least two studies by univariate analysis included
the presence of disease in both hemi-livers (P = 0.004, P =
0.001),21,28 and increased size (P = 0.02, P = 0.035)21,31 and number
(P = 0.03, P = 0.0004)22,25 of metastatic deposits. One study
reported poorer outcomes for patients with DFIs of <1 year for
metachronous presentation (P = 0.014)31 and only one study
reported the presence of synchronous disease as a predictor of
worse outcome (P = 0.0078).29
Multivariate analysis to determine independent prognostic
factors was performed in five studies (Table 4).18,21,22,25,29 Factors
found to significantly predict worse outcome in single reports
included positive resection margins (P = 0.023),18 primary tumour
serosal invasion (P = 0.02),22 primary tumour venous invasion
(P = 0.0001)25 and lymphatic invasion (P = 0.0475).25 For hepatic
metastases, independent predictors of worse outcome in single
studies were disease in both hemi-livers (P = 0.002),21 increased
number of tumour deposits (P = 0.005, P = 0.0035),22,25 metastatic
deposits 4 cm in size (P = 0.006)21 and synchronous presenta-
tion (P = 0.031).29
Discussion
Hepatic metastases are relatively common in patients with gastric
cancer. Up to 14% of all patients will have MGC to the liver at
diagnosis and, after curative resection for gastric cancer, over
a third of all patients will eventually develop liver-specific
recurrences.4–7 Currently, systemic chemotherapy is considered
the standard of care, but longterm survival with chemotherapy
alone is rare. Although recent advancements with newer regimens
for this disease have led to modest improvements, longterm
survival beyond 5 years is rarely reported.38–40
Based on estimates from published reports and known
gastric cancer incidence rates, nearly 2100 people in the USA and
99 000 individuals worldwide will present this year with hepatic
metastases. Additionally, a number of patients will eventually
develop liver metastases amenable to surgery after undergoing
a primary gastric resection. For these patients, even modest
improvements in survival compared with the survival afforded by
chemotherapy alone will represent a significant advancement in
the management of MGC. The role of liver resection for patients
with MGC is not clearly defined and resection is rarely offered to
these patients. We therefore performed a thorough review of the
literature and identified 19 studies published after 1990 in English
reporting on 436 gastric adenocarcinoma patients undergoing
liver resection with curative intent.
In retrospective analyses, biases can be introduced by selecting
patients who present with favourable prognostic factors. However,
once metastatic disease develops, it is thought to supersede the
value of primary tumour prognostic factors. In these series,
although 56% of the patients presented with small primary gastric
tumours (T1 or T2), 44% of these tumours were poorly differen-
tiated and over half had significant lymphatic and/or vascular
invasion with at least one positive lymph node involved. Thus,
although these series were highly selected, they represent a group
of patients with unfavourable biology at presentation.
Synchronous disease is a known prognostic factor representa-
tive of aggressive biology. Overall, more than half of all patients
had synchronous hepatic disease. This is higher than the 4–14%
previously reported in the literature and can be potentially
explained by the broad time range used to define synchronous
disease in these studies (up to 6 months after gastrectomy) or
the fact that these reports describe a highly selected subset of the
entire population of patients with MGC. The remainder of the
patients developed metachronous liver metastases after a median
DFI of 12.5 months. Favourable tumour biology based on the
DFI is unlikely to solely account for the encouraging outcomes
observed in this group.
Low-volume and/or localized metastatic disease may represent
a more favourable biology. Nearly two-thirds of patients in these
series underwent resection of a solitary hepatic metastasis and in
over three-quarters of cases this was localized to one hemi-liver.
This represents a biased selection of patients with relatively low-
volume and localized disease for liver resection and may explain
the unusually favourable outcomes. However, almost half of all
patients had lesions measuring >3 cm in size and several median
tumour sizes of >5 cm were reported. Additionally, the more
recent of these studies reported multiple hepatic lesions resected
in 47%, 52% and 53% of patients, respectively.28–30 These may
mitigate the selection biases based on low-volume and localized
disease in one hemi-liver. It is possible that the improvements in
hepatic surgical techniques and perioperative care utilized in the
Table 4 Prognostic factors significant on multivariate analysis
Variable P-value and study
reference
Primary tumour lymphatic invasion 0.047525
Primary tumour venous invasion 0.00125
Primary tumour serosal invasion 0.0222
Resection margins 0.02318
Unilobar vs. bilobar metastases 0.00321
Number of metastases 0.00522
0.003525
Tumour size (<4 cm vs. 4 cm) 0.00621
Synchronous vs. metachronous 0.03129
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more recent reports led to a more aggressive approach for MGC.
Nonetheless, the selection of patients with low-volume liver
disease (e.g. with single, isolated lesions measuring <5 cm, local-
ized to one hemi-liver) represents a bias that may account for the
favourable outcomes.
The potential benefits of liver resection in MGC should be
weighed against the small but not negligible risks in liver resec-
tion. In these series, a variety of liver resections were undertaken
with acceptable mortality. The combined overall 30-day operative
mortality was 3.5% (12/340 patients), but the median mortality
rate across studies was 0% and nine institutions reported no
perioperative deaths. These results compare favourably with pub-
lished mortality rates of <4% for hepatic resections in general
during the same time period.14 Although morbidity is a significant
factor in any cancer treatment and, in particular, in liver resec-
tions, the available data were insufficient to perform an adequate
analysis.
Prognostic factors can be used to select similar patients for this
aggressive approach to treating MGC to the liver. In these series of
patients undergoing hepatic resections for MGC, the following
were found to be negative prognostic factors on uni- and multi-
variate analyses in individual reports: synchronous presentation;
DFI from primary resection of <1 year; the presence of multiple or
larger metastases, and bilobar disease. However, it should be noted
that although these factors were found to be significant in one or
two studies, findings in most reports examining the same param-
eters did not reach statistical significance. Based on this analysis
and the nature of this retrospective review, no definitive conclu-
sions can be made regarding negative prognostic factors.
Although systemic therapy is considered to be the standard of
care for MGC, fewer than half of these patients received systemic
or liver-directed chemotherapy following hepatic resection. Any
improvement in survival in MGC is small with chemotherapy
alone, but it does, nevertheless, result in an increase in overall
survival compared with no treatment at all. Therefore, the survival
data reported here may potentially be underestimated. These
issues will be better addressed in a prospective randomized trial,
but no conclusions can currently be drawn regarding the value of
adjuvant chemotherapy after liver resection in MGC.
Longterm survival and the maintenance of good quality of life
are paramount in the evaluation of any modality of cancer treat-
ment. The 5-year survival of patients with gastric metastases con-
fined to the liver who are treated with systemic therapy alone is
reported to be 1.7%.12 Median survival in individual studies in this
series ranged from 9 to 34 months, and the median 5-year actu-
arial survival was 26.5% (range: 0–60%). Despite the limited
follow-up, 13.4% (48/358) of all patients were reported as still
alive 5 years following hepatic resection. Several studies with more
extended follow-up reported that 4.0% (7/174) of patients sur-
vived for >10 years. An examination of the 29 patients who sur-
vived for >5 years found that the majority had small (T1–T2;
18/26 patients), moderately to well-differentiated (20/25 patients)
tumours and underwent the removal of a single isolated meta-
static liver lesion (26/29 patients), suggesting that favourable
biology of the primary tumour in patients with a low metastatic
burden may have contributed to prolonged survival following
metastasectomy. Nonetheless, 17 of 29 patients underwent resec-
tion of synchronous lesions, including six of the seven patients
who lived for >10 years. Furthermore, only one of the studies in
this series found synchronous disease to be predictive of poor
outcome on multivariate analysis. Drawing conclusions from this
group of patients is difficult. However, these results suggest that
survival could potentially be prolonged in a similar highly selected
group of patients, even in those who present with synchronous
hepatic MGC. Currently, all of these patients would be considered
non-operable by standard-of-care criteria.
The application of an aggressive surgical approach in MGC
should also be evaluated in terms of recurrence and disease-free
survival and not only in terms of overall survival. Early or high
recurrence rates translate into prolonged periods of systemic
therapy and a potentially reduced quality of life. These will miti-
gate any short-term advantage resulting from liver resection in
MGC. It is not surprising that over three-quarters of the patients
in these series experienced a recurrence and over half (56%) suf-
fered hepatic recurrence. Based on these recurrence rates, liver
resection in MGC is less appealing. However, in these series the
majority of patients did not receive adjuvant chemotherapy after
liver resection. Given the biology and systemic nature of MGC,
this may partially account for the high recurrence rates. Recent
reports on novel chemotherapy regimens for MGC such as the
FOLFOXIRI regimen (5-fluorouracil, leucovorin, oxaliplatin
and irinotecan) are encouraging.39,40 Trials using this regimen,
although they were non-randomized and of Phase II status,
achieved for the first time a median overall survival of 15 months.
It is not unreasonable to assume that recurrence rates after liver
resection in MGC could potentially decrease with the addition of
these new regimens as adjuvant therapies.
In conclusion, the merits of liver resection in MGC should not be
dismissed reflexively simply because we have no prospective, ran-
domized data. For patients with hepatic disease amenable to sur-
gical resection, treatment alternatives include systemic chemo-
therapy, locoregional ablative therapies with or without systemic
treatment or surgical resection with or without systemic treatment.
Based on this review, it is not unreasonable to consider liver resec-
tions in MGC in highly selected patients as part of multidisci-
plinary care for this malignancy. Potential patients should be good
operative candidates with favourable tumour biology, such as small
(<5 cm) or isolated disease, long DFIs (>1 year), lesions amenable
to resection with negative margins, and no extrahepatic disease. To
better address the question of whether systemic therapy in combi-
nation with resection in limited MGC prolongs survival, the
National Cancer Institute (NCI) at the National Institutes of
Health (Bethesda, MD, USA) is currently accruing patients for the
GYMSSA trial, which will compare gastric resection and metasta-
sectomy plus FOLFOXIRI with FOLFOXIRI alone in patients with
MGC (ClinicalTrials.gov ID NCT00941655).41
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